As of November 6, 2026, Odyssey Therapeutics, Inc. is a publicly traded company (Nasdaq: ODTX). The largest holder reporting an active stake on Schedule 13D is SR One Capital Management, LLC, at 8%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Fidelity (FMR) (13%), Lightspeed Venture Partners XV-B (Ignite), L.P. (7.6%) (Schedule 13D, May 18, 2026).
Is this your company?
About to sign with, pay or invest in Odyssey Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Odyssey Therapeutics, Inc. a real, registered company?
- Odyssey Therapeutics, Inc. files with the SEC under CIK 1882782 (its SEC filings).
- Its shares are listed under the ticker ODTX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Boston, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Odyssey Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are Odyssey Therapeutics, Inc.'s owners and officers?
Odyssey Therapeutics, Inc.: incorporated in Delaware; business address in Boston, Massachusetts; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-11-05).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-12-04)
- : Director (Form D, 2025-12-04)
- : Director (Form D, 2025-12-04)
- : Director (Form D, 2025-12-04)
- : Director (Form D, 2025-12-04)
- : Director (Form D, 2025-12-04)
- : Director (Form D, 2025-12-04)
- : Director (Form D, 2025-12-04)
- : Director (Form D, 2025-12-04)
- : Director (Form D, 2025-12-04)
- : Director (Form D, 2025-12-04)
- : Director (Form D, 2025-12-04)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 13% |
| Schedule 13G, 2026-06-05 | Fmr LLC | 10.2% |
| Schedule 13D, 2026-05-18 | Tpg Gp A, LLC | 7.8% |
| Schedule 13D, 2026-05-18 | Sr One Capital Management, LLC | 8% |
| Schedule 13G, 2026-05-18 | Lightspeed Venture Partners Xv-B (Ignite), L.P. | 7.6% |
| Schedule 13D, 2026-05-15 | Dimension Capital Ii, L.P. | 7.1% |
| Schedule 13D, 2026-05-15 | Jeito Ii S.L.P. | 7.8% |
Questions about who owns Odyssey Therapeutics, Inc.
Who owns Odyssey Therapeutics, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Odyssey Therapeutics, Inc.: Fmr LLC (13%, Schedule 13G/A, filed 2026-11-05), Sr One Capital Management, LLC (8%, Schedule 13D, filed 2026-05-18), Tpg Gp A, LLC (7.8%, Schedule 13D, filed 2026-05-18), Jeito Ii S.L.P. (7.8%, Schedule 13D, filed 2026-05-15) and Lightspeed Venture Partners Xv-B (Ignite), L.P. (7.6%, Schedule 13G, filed 2026-05-18); 1 more is listed above.
Who are the largest shareholders of Odyssey Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Odyssey Therapeutics, Inc. on this page are Fmr LLC (13%), Sr One Capital Management, LLC (8%) and Tpg Gp A, LLC (7.8%).
When did Fmr LLC buy into Odyssey Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2026-06-05, reporting 10.2%; its latest, Schedule 13G/A filed 2026-11-05, reports 13%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Odyssey Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Odyssey Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Odyssey Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Odyssey Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- SR One Capital Management, LLC, a 10% owner: 3,794,883 shares (7.9% of shares outstanding), held indirectly through a see note 2, on a joint filing (Form 4, 2026-05-11).
- , a 10% owner: 3,794,883 shares (7.9% of shares outstanding), held indirectly through a see note 2, on a joint filing (Form 4, 2026-05-11).
- TPG GP A, LLC: 3,690,146 shares (7.7% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-05-13).
- James G. Coulter: 3,690,146 shares (7.7% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-05-13).
- Jon Winkelried: 3,690,146 shares (7.7% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-05-13).
Shares outstanding: 48,067,877 as of 2026-11-02, from the company's latest SEC cover page.
How much has Odyssey Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-12-04 | $214.03M | $214.03M |
| Form D, 2023-12-15 | $97.13M | $106M |
| Form D, 2022-10-27 | $168.01M | $174.91M |
Latest IPO step: Odyssey Therapeutics, Inc. filed its final IPO prospectus, ticker ODTX (424B4, 2026-05-08).
IPO filings: 424B4, 2026-05-08, S-1/A, 2026-05-04, S-1, 2026-04-17, RW, 2025-06-09, S-1, 2025-01-17; ticker ODTX on Nasdaq Capital Market.
Keep reading
More on Odyssey Therapeutics, Inc. and the records around it.
The people at Odyssey Therapeutics, Inc.
- Shelley Chu is also named on 1 other Form D filing: Antares Therapeutics, Inc. (May 2025)
Odyssey Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- IPO filing May 2026
- Form D filing Dec 2025
Companies that share a holder
- SR One Capital Management, LLC also filed stake reports on 6 other companies: ADARx Pharmaceuticals, Inc. (Oct 2026), Zenas BioPharma, Inc. (Aug 2026), Veradermics, Inc. (Aug 2026)
- TPG GP A, LLC also filed stake reports on 15 other companies: Allogene Therapeutics, Inc. (Sep 2026), TPG Inc. (Aug 2026), Ceribell, Inc. (Aug 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/odyssey-therapeutics